Intranasal COVID-19 vaccine | ALS | Bacteria in cells

National Institutes of Health (NIH) sent this bulletin at 08/10/2021 02:30 PM EDT

Having trouble viewing this email? View it as a Web page.

August 10, 2021 Edition

We at NIH are doing everything we can toward the development of diagnostics, therapeutics, and vaccines for COVID-19. You can find the latest public health information from CDC at https://www.cdc.gov/coronavirus and the latest research information from NIH at https://www.covid19.nih.gov. Meanwhile, science continues to progress on many other fronts, and we will continue to try to bring you stories across a wide range of topics.

Transmission electron microscope image of SARS-CoV-2

Intranasal COVID-19 vaccine effective in animal studies

A nasal spray of the Oxford/AstraZeneca COVID-19 vaccine protected hamsters and monkeys against serious disease and reduced the amount of virus in the nose.

Cellular defect found in inherited and sporadic ALS

In lab-grown neurons derived from people with inherited or sporadic ALS, buildup of a protein called CHMP7 in the nucleus led to cellular damage.

Rod-shaped bacteria packed inside a cell

Detergent-like protein kills bacteria in human cells

Researchers identified a protein that acts like a detergent to kill bacteria inside human cells.

Connect with us:

Facebook

RSS Feed

Update Your E-mail Address | Add Subscriptions | Unsubscribe All

If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com. For all other inquiries about NIH programs and activities, please contact Ask NIH. Before writing, please view our Frequently Asked Questions page, our Health Information page, or Search our website.